Visa Inc vs State Street SPDR S&P Biotech ETF — how do they compare? Visa Inc trades at $361 (market cap $671.74B), while State Street SPDR S&P Biotech ETF trades at $158.21. The key difference: Visa Inc pays a 0.74% dividend while State Street SPDR S&P Biotech ETF pays none. Which is the better fit depends on your goals.
| V | XBI | |
|---|---|---|
Market Cap | $671.74B | — |
Volume | 10,431,336 | — |
Sector | Financials | Broad Market / Factor |
52-Week High | $370.47 | $164.28 |
52-Week Low | $295.52 | $86.92 |
Enterprise Value | $682.32B | — |
Dividend Yield | 0.74% | — |
Signals from Pluang's Aura AI — not financial advice
Visa (V) trades at $361.32, down 0.33% on the day, with a bearish technical signal but strong fundamentals. The stock shows consistent earnings beats, with Q2 2026 EPS of $3.32 exceeding the $3.23 estimate. Revenue grew to $40 billion in 2025, with a net income margin of 50.78%. Recent news highlights Visa's AI initiatives, such as Intelligent Commerce Connect, to enhance payment efficiency.
The outlook remains positive due to high analyst buy ratings (85.48%) and a consensus price target of $426.31, implying 18% upside. Risks include fintech competition and regulatory pressures, but Visa's robust cash flow and profitability support long-term growth potential for investors.
No Aura AI signal available yet.
Trailing returns across standard periods
Latest headlines on both assets
Visa Inc. operates a retail electronic payments network and manages global financial services. The Company also offers global commerce through the transfer of value and information among financial institutions, merchants, consumers, businesses, and government entities.
Read more on V →XBI is an equal-weighted ETF that tracks the U.S. biotechnology segment. It provides diversified exposure to small, mid, and large-cap biotech firms involved in drug discovery and medical research, such as Moderna and Exact Sciences.
Read more on XBI →